Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly COVID-19 Neutralizing Antibody Combo’s Reduced Infusion Time Offers Advantages For Providers

Feb 10 2021

• By Joseph Haas

Coronavirus — Lilly is testing the antibody combo against all variants seen in the US

Related Content

EMA Reviewing Two MAb Combinations For COVID-19

Feb 08 2021

US FDA Authorizes Lilly’s COVID-19 mAB Combo For Lower Doses Than Tested In Phase III

Feb 11 2021

Big COVID-19-Related Sales Drive Lilly’s Strong Q4 Performance

Jan 29 2021

Coronavirus Update: Lilly’s Antibody EUA Adds To ‘Turnaround’ Hopes On Pandemic

Nov 10 2020

Regeneron And Lilly Are Back With Better COVID-19 Antibody Data – But Still Face Medical Skepticism

Feb 09 2021

Related Companies

Eli Lilly and Company

Amgen, Inc.

AbCellera Biologics Inc.

Regeneron Pharmaceuticals, Inc.

Additional Topics

Coronavirus COVID-19 Approvals BioPharmaceutical

More from COVID-19

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.